Communiqués Kintara Therapeutics, Inc.

Actions

KTRA

US49720K2006

Temps réel estimé Cboe BZX 16:12:10 16/09/2026			Varia. 5j.	Varia. 1 janv.
2,045 ^USD	+0,74%		-4,25%	-72,81%

14/11/24	Kintara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 30 septembre 2024	CI
17/10/24	TuHURA Biosciences, Inc. a conclu l'acquisition de Kintara Therapeutics, Inc. (NasdaqCM:KTRA) dans le cadre d'une opération de fusion inversée.	CI

Communiqués

15/06	Kintara Therapeutics : TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers	PU
19/05	Kintara Therapeutics : Corporate Presentation (HURA Investor Deck Final May 2026)	PU
15/05	Kintara Therapeutics : TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update	PU
06/03	Kintara Therapeutics : Corporate Presentation (HURA Corporate Deck March 2026 FINAL)	PU
15/01	Kintara Therapeutics : Corporate Presentation (TuHURA Corporate Deck JPM 2026 FINAL)	PU
12/12/24	Kintara Therapeutics : TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc Form 8 K	PU
24/10/24	TuHURA Biosciences Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC	AQ
23/10/24	TuHURA Biosciences to Present at the Virtual Investor New to the Street Event	AQ
21/10/24	Kintara Therapeutics : TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics Form 8 K	PU
16/10/24	Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024	AQ
15/10/24	Kintara Therapeutics : Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 Form 8 K	PU
15/10/24	Kintara Therapeutics : Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 Form 8 K	PU
09/10/24	Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update	AQ
08/10/24	Kintara Therapeutics : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 8 K	PU
08/10/24	Kintara Therapeutics : Announces Fiscal 2024 Financial Results and Provides Corporate Update Form 8 K	PU
07/10/24	Kintara Therapeutics : Annual Report for Fiscal Year Ending June 30, 2024 (Form 10-K)	PU
04/10/24	Kintara Therapeutics : Proxy Results Form 8 K	PU
23/09/24	Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024	AQ
19/09/24	Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences	AQ
12/09/24	Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study	AQ
20/08/24	TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer	AQ
12/07/24	Kintara Therapeutics : Certificate of Incorporation/Bylaws Form 8 K	PU
09/07/24	TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor	AQ
02/07/24	Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline near Term Milestones	AQ
10/05/24	Kintara Therapeutics : Shareholder Meeting - Form 8-K	PU